We believe that chicken antibodies are an unexploited source of new therapeutics that could save one million lives before 2025.

To capture the full potential of chicken antibodies, we have designed a multidisciplinary approach that combines bioinformatics, chemistry, physics, as well as biology, to create the best antibodies. Our platform welcomes outside projects to create new synergies and amplify our impact on human health. Through our Nebula platform, we discover and engineer chicken antibodies that target difficult proteins with an unexploited therapeutic potential. There are about 600 to 1500 genes that are both involved in a disease and that are druggable. From these targets, there are around 400 genes historically known to be difficult, but with a huge therapeutic potential, such as the G protein-coupled receptors or GPCRs, ion channels and integrins.

To circumvent these historical bottlenecks, we have designed 4 families of technologies to create antibodies against these high potential targets:

  1. Smart antigens, such as Spatial Peptides that replicate the native 3D structure of the target.
  2. Chicken antibodies as a novel source of therapeutics.
  3. Phage display technologies to select the best antibodies.
  4. And Humanization technologies to engineer the perfect immunotherapy agents.

With these technologies, we can address these 400 targets already validated for the diagnosis and treatment of a wide range of diseases.


Development Phases


Contact : Frédéric Leduc
Phone: +1 855 346-3449 ext. 700

Web site:

221, Rue Tobin
Sherbrooke, Québec
J1C 0K9